Impact of COVID-19 therapy on hyperglycemia
Diabetes and Vascular Disease Research · 2022-05 · 19 (3)
DOI: 10.1177/14791641221095091 ↗Kurz gefasst
Editorial in der Zeitschrift Diabetes and Vascular Disease Research, online erschienen am 13.06.2022. Verfasst von Rachel Parise und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery and Development, 15460Auburn University Harrison School of Pharmacy, Auburn, AL, USA. Hauptthemen laut MEDLINE: COVID-19, Diabetes Mellitus, Hyperglycemia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The goal of this study was to analyze the effect of COVID-19 drugs and biologicals on hyperglycemia. A literature search with key terms, such as “COVID-19 drugs and hyperglycemia” and “COVID-19 vaccines and hyperglycemia,” was conducted using PubMed through September 2021. The CDC data were referenced for current COVID-19 profile and statistics. The NIH COVID-19 guidelines were referenced for updated treatment recommendations. Micromedex and UpToDate were used for drug and disease information. Current results suggested that corticosteroids (dexamethasone), remdesivir and antivirals (lopinavir and ritonavir) all have the potential to significantly raise blood glucose levels putting patients at elevated risk for severe complications. In contrary, hydroxychloroquine is associated with hypoglycemia, and tocilizumab decreases inflammation which is associated with improving glucose levels. Other anti-cytokine bioactive molecules are correlated with lower blood glucose in patients with and without diabetes mellitus. Ivermectin, used for mild COVID-19 disease, possesses the potential for lowering blood glucose. Covishield, Pfizer-BioNTech, and Moderna have all been associated with hyperglycemia after the first dose. Individualized /personalized patient care is required for diabetic mellitus patients with COVID-19 infection. Improper drug therapy aggravates hyperglycemic conditions and other comorbid conditions, leading to increased morbidity and mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Drug Discovery and Development, 15460Auburn University Harrison School of Pharmacy, Auburn, AL, USA.
- Department of Cardiology, 92323Zhongshan Hospital Fudan University, Shanghai, China.
- Department of Laboratory Medicine and Pathology, 7284University of Washington, Seattle, WA, USA.
ORCID-Profile: Muralikrishnan Dhanasekaran
Zitieren
APA
Parise, R., Deruiter, J., Ren, J., Govindarajulu, M., Ramesh, S., Nadar, R. M., Moore, T., & Dhanasekaran, M. (2022). Impact of COVID-19 therapy on hyperglycemia. Diabetes and Vascular Disease Research, 19(3). https://doi.org/10.1177/14791641221095091
Vancouver
Parise R, Deruiter J, Ren J, Govindarajulu M, Ramesh S, Nadar RM, et al. Impact of COVID-19 therapy on hyperglycemia. Diabetes and Vascular Disease Research. 2022;19(3). doi:10.1177/14791641221095091
BibTeX
@article{Parise2022,
author = {Parise, Rachel and Deruiter, Jack and Ren, Jun and Govindarajulu, Manoj and Ramesh, Sindhu and Nadar, Rishi M and Moore, Timothy and Dhanasekaran, Muralikrishnan},
title = {Impact of COVID-19 therapy on hyperglycemia},
journal = {Diabetes and Vascular Disease Research},
year = {2022},
volume = {19},
number = {3},
doi = {10.1177/14791641221095091}
}
EUVIMED